View Clinical Trial (Medical Research Study)

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated IOP on a Prostaglandin - NCT00759941-76134(Clinical Trial 243353)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Fort Worth
State:  
TX
Zip Code: 76134
Conditions: Glaucoma
Purpose: Assess safety and efficacy of transitioning uncontrolled glaucoma patients currently on Xalatan to adding either Azopt or Placebo TID.
Study summary:
Criteria: Inclusion Criteria: - Unilateral or bilateral primary open angle glaucoma, ocular hypertension or pseudoexfoliation syndrome - IOP > 18mm Hg (mean diurnal) and less than 32 mm Hg Exclusion: - Previous intraocular surgery, Except uncomplicated clear cornea phacoemulsification or argon laser trabeculoplasty - Argon laser trabeculoplasty or phacoemulsification within the last 3 months - Central corneal thickness outside the 500 - 600 (inclusive) micron range as measured by ultrasonic pachymetry - Ocular or periocular inflammation within 3 months prior to study (except blepharitis related or seasonal allergic conjunctivitis) - History of uveitis or previous intraocular inflammation (other than post-operatively) - Hypersensitivity to sulfa, or benzalkonium chloride - History of use of any steroids for over 1 week within 3 months of screening or likely need for any corticosteroids during the study (except inhaled, nasal or topical non-ocular)
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: January 20, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.